PTI-1 explained

PTI-1 (SGT-48) is an indole-based synthetic cannabinoid.^[1] It is one of few synthetic cannabinoids containing a thiazole group and is closely related to PTI-2. These compounds may be viewed as simplified analogues of indole-3-heterocycle compounds originally developed by Organon and subsequently further researched by Merck.^{[2] [3] [4]}

See also

• JWH-018
• LBP-1 (drug)
• PTI-2

Notes and References

1. Web site: PTI-1 . Cayman Chemical . 8 July 2015.
2. US . 7700634 . (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor. . Adam-Worrall J, Morrison AJ, Wishart G, Kiyoi T, McArthur DR . Organon NV . 20 April 2010 .
3. US . 7763732 . Indole Derivatives . Paul David Ratcliffe PD, Adam-Worrall J, Morrison AJ, Francis SJ, Kiyoi T . Organon NV . 27 July 2010 .
4. Kiyoi T, Adam JM, Clark JK, Davies K, Easson AM, Edwards D, Feilden H, Fields R, Francis S, Jeremiah F, McArthur D, Morrison AJ, Prosser A, Ratcliffe PD, Schulz J, Wishart G, Baker J, Campbell R, Cottney JE, Deehan M, Epemolu O, Evans L . 6 . Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists . Bioorganic & Medicinal Chemistry Letters . 21 . 6 . 1748–53 . March 2011 . 21316962 . 10.1016/j.bmcl.2011.01.082 .